Adlai Nortye Announces Publication of Preclinical Research of AN3025 (anti-hTNFR2）in Frontiers in Immunology

NORTH BRUNSWICK, N.J. and HANGZHOU, China, Feb. 21, 2022 /PRNewswire/ -- recently -- Adlai Nortye Ltd. ("Adlai Nortye"), a clinical-stage biopharmaceutical company focused on the development of innovative cancer therapies, announced the publication of preclinical research of AN3025 (anti-hTNFR2）...